Physician profile
Sara Tal
NPI 1528307535
$11,154.75
in general payments reported to CMS, 2019-2025
45 companies · $3,432 in 2025
The $3,432 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,601 · 2022: $1,164 · 2023: $913 · 2024: $3,044 · 2025: $3,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,389.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,223.19 | 2021-2025 | |
| Lundbeck LLC | $924.47 | 2021-2025 | Vyepti |
| Sk Life Science, INC. | $693.72 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $532.27 | 2021 | |
| Lilly USA, LLC | $500.05 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $466.29 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $451.12 | 2021-2025 | Crexont, Rytary, Ongentys |
| Axsome Therapeutics, INC. | $255.65 | 2025 | Symbravo |
| Eisai INC. | $251.33 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $244.59 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $242.87 | 2021-2022 | |
| Biogen, INC. | $233.59 | 2021-2024 | Skyclarys, Aduhelm |
| Biohaven Pharmaceutical Holding Company Ltd. | $224.66 | 2022 | |
| Almatica Pharma LLC | $177.47 | 2021-2023 | Gralise |
| Ucb, INC. | $167.76 | 2024-2025 | Briviact, Rystiggo, Nayzilam |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Tal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.